Salvage radiation therapy after radical prostatectomy with the use of new technologies in radiation oncology


Cite item

Full Text

Abstract

Introduction: prostate cancer (PCa) is the second cancer after lung one among all males. The main treatmentfor patients with localized prostate cancer is a radical prostatectomy (RP). After RP PCa occurs in patients at the T1-T2 stage - in 25 - 35% of all cases and in patients at the T3 stage - in 33.5 - 66% of all cases. Currently, one of the treatment options for patients with recurrence PCa after RP is a «salvage» radiation therapy. Materials and methods: medical records of 59 patients with PCa recurrence after radical prostatectomy (pT1-3pN0M0) were analyzed. Biochemical recurrence was observed in 25 (42,4%) and clinical recurrence in 34 (57,6%) patients. Radiotherapy have been prescribed to the regional lymphatic nodes to 44,0 Gy of 2,0 Gy each, to the prostate bed to 66,0 Gy of 2,0 Gy each and if the region of the clinical recurrence was identified - to 72 Gy of 2,0 Gy. Treatment was realized on linear electron accelerators using 3D technology radiotherapy: 3DCRT, IMRT, VMAT. Results: all 59 patients were treated by the «salvage» radiotherapy. Median follow-up was 48 months (24-91). Biochemical control w as achieved in 51 (86.4%) patients, locoregional control in 58 (98.3%) patients. No acute and late grade 3 or greater toxicities were observed.

About the authors

S. I Tkachev

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

V. B Matveev

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

Petr V. Bulychkin

N.N. Blokhin Russian Cancer Research Center

Email: pert_mma@mail.ru
Radiologist of the Radiology Department of the Research Institute of Clinical Oncology Moscow, 115478, Russian Federation

References

  1. Давыдов М.И. Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2012 г. В кн.: Давыдов М.И. Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. М.: Издательская группа РОНЦ; 2014; 48.
  2. Makarov D.V., Trock B.J., Humphreys E.B., Mangold L.A., Walsh P.C., Epstein J.I. et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate - specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007; 69 (6): 1095-101.
  3. Joniau S., Hsu C.Y., Lerut E., Van Baelen A., Haustermans K., Roskams T. et al. A pretreatment table for the prediction of final histopothology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur. Urol. 2007; 51 (2): 388-96.
  4. Cookson M.S., Aus G., Bernett A.L., Candy-Hagino E.D., D’Amico A.V., Dmochowski R.R. et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer. The American Urological Association Prostate Guidelines for Localized Prostate Cancer. Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes. J. Urol. 2007. 177 (2): 540-5.
  5. Boccon-Gibod L., Djavan W.B., Hammerer P., Hoeltl W., Kattan M.W., Prayer-Galetti T. et al. Management of prostate-specific antigen relase in prostate cancer: a European Consensus. Int. J. Clin. Pract. 2004. 58 (4): 382-90.
  6. Schild S.E., Wong W.W., Grado G.L., Buskirk S.J., Robinow J.S., Frick L.M. et al. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin. Proc. 1994; 69 (7): 613-9.
  7. Cadeddu J.A., Partin A.W., De Weese Y.L., Walsh P.C. Longterm results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J. Urol. 1998; 159 (1): 173-7.
  8. Pisansky T.M., Kozelsky T.F., Myers R.P., Hillman D.W., Blute M.L., Buskirk S.J. et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J. Urol. 2000; 163 (3): 845-50.
  9. Michalski J.M., Lawton C., El Naqa I., Ritter M., OMeara E., Seider M.J. et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010; 76 (2): 361-8.
  10. Poortmans P., Bossi A.,Vandeputte K., Bosset M., Miralbell R., Maingon P. et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother. Oncol. 2007; 84 (2): 121-7.
  11. Morgan-Fletcher S.L. Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50). Br. J. Radiol. 2001; 74: 294.
  12. Cox J.D., Stets J., Pajak T.F. et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys. 1995; 31 (5): 1341-6.
  13. Trock B.J., Han M., Freedland S.J., Humphreys E.B., DeWeese T.L. et al. Prostate cancer specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. J.A.M.A. 2008; 299 (23); 2760-9.
  14. Boorjian S.A., Karnes R.J., Crispen P.L., Rangel L.J., Bergstralh E.J., Blute M.L. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J. Urol. 2009; 182 (6): 2708-15.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies